Supernus Pharm (SUPN) 21.87 $SUPN
Supernus' Trokendi XR Gets FDA Nod for Migraine in Adults
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 8:52AM CDT
Supernus Pharmaceuticals, Inc. (SUPN) announced that the FDA has granted a tentative approval to the company's sNDA for a label expansion for Trokendi XR to include prophylaxis of migraine headache in adults.
ANIP: 60.27 (-1.15), SUPN: 21.87 (-0.16), CORT: 5.30 (-0.05), PCRX: 39.38 (-0.99)
Supernus Announces Resignation of Dr. James Barrett from Board of Directors; Charles W. Newhall, III Elected Chairman
GlobeNewswire - Fri Aug 12, 3:15PM CDT
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that Dr. M. James Barrett, Ph.D., has resigned from its Board of Directors effective August 10, 2016.
SUPN: 21.87 (-0.16)
AmerisourceBergen (ABC) Earnings, Revenues Beat in Q3
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 4:05PM CDT
AmerisourceBergen Corporation (ABC) posted earnings (excluding one-time items) of $1.37 per share in the third quarter of fiscal 2016 (ended Jun 30, 2016), beating the Zacks Consensus Estimate of $1.26
IPXL: 23.63 (-0.31), ABC: 87.53 (+0.38), WBA: 81.85 (+0.31), SUPN: 21.87 (-0.16)
Mallinckrodt (MNK) Tops Q3 Earnings on Solid Sales Growth
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 3:51PM CDT
Mallinckrodt plc (MNK) reported adjusted earnings of $2.20 per share in the third quarter of fiscal 2016 (ended Jun 24, 2016), beating the Zacks Consensus Estimate of $2.01.
MNK: 73.55 (-2.04), IPXL: 23.63 (-0.31), SUPN: 21.87 (-0.16), MYL: 40.38 (-1.54)
Supernus Announces Second Quarter 2016 Financial Results
GlobeNewswire - Tue Aug 02, 3:30PM CDT
-- Second quarter 2016 product prescriptions totaled 123,758, a 38.9% increase over the second quarter of 2015.
SUPN: 21.87 (-0.16)
Supernus Announces Issuance of Seventh U.S. Patent Protecting Oxtellar XR(R)
GlobeNewswire - Wed Jun 22, 3:30PM CDT
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced the issuance on June 21, 2016 of a seventh patent (number 9,370,525) by the United States Patent and Trademark Office (USPTO) covering Oxtellar XR, its novel once-daily extended-release oxcarbazepine product. The patent provides protection for the product with expiration that is no earlier than 2027.
SUPN: 21.87 (-0.16)
Supernus Provides Update on Trokendi XR(R) Migraine sNDA and Reiterates Guidance
GlobeNewswire - Thu Jun 16, 3:30PM CDT
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that it remains in discussions with the FDA regarding its Supplemental New Drug Application, or sNDA, for migraine. The FDA requested that the Company resubmit the Trokendi XR product label with migraine as an indication in a different format prior to completing its review. No additional new data, studies or analyses for efficacy or safety were requested by the FDA.
SUPN: 21.87 (-0.16)
Supernus Announces Issuance of Sixth U.S. Patent Protecting Oxtellar XR(R)
GlobeNewswire - Thu Jun 02, 7:00AM CDT
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced the issuance on May 31, 2016 of a sixth patent (number 9,351,975) by the United States Patent and Trademark Office (USPTO) covering Oxtellar XR, its novel once-daily extended-release oxcarbazepine product. The patent provides protection for the product with expiration that is no earlier than 2027.
SUPN: 21.87 (-0.16)
Supernus to Present at June Jefferies Healthcare Conference
GlobeNewswire - Tue May 24, 4:16PM CDT
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present an overview and update of the Company and host investor meetings at the Jefferies 2016 Healthcare Conference.
SUPN: 21.87 (-0.16)
Supernus Enters Into Partial Settlement Agreement with Actavis on Oxtellar XR(R)
GlobeNewswire - Tue May 10, 7:30AM CDT
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that, pursuant to a confidential partial settlement agreement, it has dismissed two patent infringement actions pending in the U.S. District Court for the District of New Jersey against Actavis Inc. and its subsidiaries. The dismissed actions concerned two of Supernus' Orange Book patents covering Oxtellar XR(R)--U.S. Patent Nos. 8,821,930 and 9,119,791. The parties also agreed to dismiss Actavis' pending appeal (and Supernus' corresponding cross-appeal) of a February 2016 district court ruling that a third Oxtellar XR patent--U.S. Patent No. 8,617,600--is valid, but not infringed by Actavis' proposed generic version of Oxtellar XR. The February 2016 district court decision additionally found that Actavis infringed two other Oxtellar XR Orange Book patents (U.S. Patent Nos. 7,722,898 and 7,910,131), and enjoined Actavis from launching a generic version of Oxtellar XR until at least April 13, 2027. Actavis' appeal of that ruling will proceed as scheduled.
ACT: 298.98 (-2.94), SUPN: 21.87 (-0.16)
Supernus Announces First Quarter 2016 Financial Results
GlobeNewswire - Tue May 03, 4:00PM CDT
-- First quarter 2016 product prescriptions totaled 114,773, representing a 49.7% increase over the first quarter of 2015.
SUPN: 21.87 (-0.16)
Supernus to Host First Quarter 2016 Earnings Conference Call
GlobeNewswire - Tue Apr 19, 11:01AM CDT
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report the financial results for the first quarter of 2016 after 5:00 PM ET on Tuesday, May 3, 2016.
SUPN: 21.87 (-0.16)
Supernus Pharmaceuticals Selects DSG, Inc. for EDC and IWRS in Phase 3 Clinical Studies on Impulsive Aggression in Pediatric Patients Treated for Attention Deficit/Hyperactivity Disorder (ADHD)
BusinessWire - Fri Apr 01, 7:00AM CDT
DSG, a leader in electronic data capture (EDC), was selected by Supernus Pharmaceuticals, a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, to provide a fully supported eCaseLink EDC system, including IWRS Web-based Randomization-Clinical Supply, a Central lab and third-party CRO data integration, and data management services for two blinded Phase 3 clinical studies on impulsive aggression in pediatric patients being treated for Attention Deficit/Hyperactivity Disorder (ADHD). Leveraging pieces of DSG's eCaseLink system (EDC and IWRS) will allow Supernus to significantly reduce clinical trial time, reduce trial cost, improve trial accuracy, and overall provide a more effective clinical trial with greater impact.
SUPN: 21.87 (-0.16)
Covered Call Alerts For Starbucks, GW Pharmaceuticals, Supernus Pharmaceuticals, CSX and SunEdison Released By InvestorsObserver
PR Newswire - Tue Feb 09, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for SBUX, GWPH, SUPN, CSX and SUNE.
SBUX: 56.03 (-0.28), GWPH: 82.80 (+0.52), SUNE: 0.34 (unch), SUPN: 21.87 (-0.16), CSX: 28.15 (-0.03)
Latest Global Supernus Pharmaceuticals, Inc. Market Research Report Product Pipeline Review 2016 - Acute Market Reports
M2 - Fri Jan 29, 7:33AM CST
'SUPERNUS PHARMACEUTICALS, INC. - Product Pipeline Review - 2015', provides an overview of the SUPERNUS PHARMACEUTICALS, INC.'s pharmaceutical research and development focus.
SUPN: 21.87 (-0.16)
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/jxcczv/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Attention Deficit Hyperactivity Disorder (ADHD) Overview - Therapeutics Development - Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Overview - Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Comparative Analysis - Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Development by Companies - Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Investigation by Universities/Institutes - Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Attention Deficit Hyperactivity Disorder (ADHD) - Products under Development by Companies - Attention Deficit Hyperactivity Disorder (ADHD) - Products under Investigation by Universities/Institutes - Attention Deficit Hyperactivity Disorder (ADHD) - Companies Involved in Therapeutics Development - Alcobra Ltd - Amarantus Bioscience Holdings, Inc. - APeT Holding BV - Arbor Pharmaceuticals, LLC. - BCWorld Pharm Co. Ltd. - Collegium Pharmaceutical, Inc. - Curemark, LLC - Domain Therapeutics SA - DURECT Corporation - H. Lundbeck A/S - Heptares Therapeutics Limited - Highland Therapeutics, Inc. - Hisamitsu Pharmaceutical Co., Inc. - Integrative Research Laboratories Sweden AB - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Luc Therapeutics, Inc. - Medgenics Inc. - Merck & Co., Inc. - Neos Therapeutics, Inc. - NeuroDerm Ltd. - Neurovance, Inc. - P2D Bioscience - Polleo Pharma Limited - Reviva Pharmaceuticals Inc. - Samyang Biopharmaceuticals Corporation - Shire Plc - Signature Therapeutics, Inc - Sunovion Pharmaceuticals Inc. - Supernus Pharmaceuticals, Inc. - Taisho Pharmaceutical Holdings Co., Ltd. - Tris Pharma, Inc. - Vernalis Plc For more information visit http://www.researchandmarkets.com/research/jx...on_deficit
KMPH: 4.59 (+0.15), MDGN: 5.58 (+0.05), ADHD: 4.83 (+0.09), SUPN: 21.87 (-0.16), COLL: 8.92 (+0.09), DRRX: 1.64 (+0.03), NEOS: 6.90 (-0.20), NDRM: 16.23 (-0.03), MRK: 62.75 (-0.15), SHPG: 191.97 (+3.47), ITCI: 40.35 (-0.28)
Supernus Announces Distribution of Common Stock by NEA
GlobeNewswire - Fri Dec 04, 8:00AM CST
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that it has received notice that, effective following the close of trading on December 3, 2015, New Enterprise Associates (NEA) distributed an aggregate of 3,820,625 shares of Supernus Pharmaceuticals common stock to its partners, and as a result no longer holds common stock in the company. "The distribution announced today is the third and final installment of a distribution that NEA initiated earlier this year and is consistent with its customary practices. NEA distributed shares of Supernus common stock to its limited partners after holding that position for over nine years," stated Jack Khattar, president and chief executive officer of Supernus.
SUPN: 21.87 (-0.16)
Supernus to Attend Guggenheim Securities Boston Healthcare Conference
GlobeNewswire - Wed Dec 02, 3:30PM CST
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will be hosting investor meetings at the Guggenheim Securities 3 Annual Boston Healthcare Conference 2015.
SUPN: 21.87 (-0.16)
Supernus reports distribution of 3,820,625 common stock through NEA
M2 - Fri Nov 13, 3:28AM CST
Supernus Pharmaceuticals (NasdaqGM:SUPN) on Thursday announced the distribution of an aggregate of 3,820,625 common stock with the close of trading on 11 November 2015.
SUPN: 21.87 (-0.16)
Supernus Pharmaceuticals Is Dropping -- Is It a Buy?
Todd Campbell, The Motley Fool - Motley Fool - Thu Nov 12, 12:26PM CST
What: A bit more than a week after reporting earnings and ahead of an investor conference next week, shares in Supernus Pharmaceuticals fell by 13% earlier today. Let's take a closer look at this company and whether or not investors ought to...
GWPH: 82.80 (+0.52), SUPN: 21.87 (-0.16)
Supernus' Trokendi XR Gets FDA Nod for Migraine in Adults
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 8:52AM CDT
Supernus Pharmaceuticals, Inc. (SUPN) announced that the FDA has granted a tentative approval to the company's sNDA for a label expansion for Trokendi XR to include prophylaxis of migraine headache in adults.
ANIP: 60.27 (-1.15), SUPN: 21.87 (-0.16), CORT: 5.30 (-0.05), PCRX: 39.38 (-0.99)
Supernus Announces Resignation of Dr. James Barrett from Board of Directors; Charles W. Newhall, III Elected Chairman
GlobeNewswire - Fri Aug 12, 3:15PM CDT
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that Dr. M. James Barrett, Ph.D., has resigned from its Board of Directors effective August 10, 2016.
SUPN: 21.87 (-0.16)
AmerisourceBergen (ABC) Earnings, Revenues Beat in Q3
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 4:05PM CDT
AmerisourceBergen Corporation (ABC) posted earnings (excluding one-time items) of $1.37 per share in the third quarter of fiscal 2016 (ended Jun 30, 2016), beating the Zacks Consensus Estimate of $1.26
IPXL: 23.63 (-0.31), ABC: 87.53 (+0.38), WBA: 81.85 (+0.31), SUPN: 21.87 (-0.16)
Mallinckrodt (MNK) Tops Q3 Earnings on Solid Sales Growth
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 3:51PM CDT
Mallinckrodt plc (MNK) reported adjusted earnings of $2.20 per share in the third quarter of fiscal 2016 (ended Jun 24, 2016), beating the Zacks Consensus Estimate of $2.01.
MNK: 73.55 (-2.04), IPXL: 23.63 (-0.31), SUPN: 21.87 (-0.16), MYL: 40.38 (-1.54)
Supernus Announces Second Quarter 2016 Financial Results
GlobeNewswire - Tue Aug 02, 3:30PM CDT
-- Second quarter 2016 product prescriptions totaled 123,758, a 38.9% increase over the second quarter of 2015.
SUPN: 21.87 (-0.16)
Supernus Announces Issuance of Seventh U.S. Patent Protecting Oxtellar XR(R)
GlobeNewswire - Wed Jun 22, 3:30PM CDT
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced the issuance on June 21, 2016 of a seventh patent (number 9,370,525) by the United States Patent and Trademark Office (USPTO) covering Oxtellar XR, its novel once-daily extended-release oxcarbazepine product. The patent provides protection for the product with expiration that is no earlier than 2027.
SUPN: 21.87 (-0.16)
Supernus Provides Update on Trokendi XR(R) Migraine sNDA and Reiterates Guidance
GlobeNewswire - Thu Jun 16, 3:30PM CDT
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that it remains in discussions with the FDA regarding its Supplemental New Drug Application, or sNDA, for migraine. The FDA requested that the Company resubmit the Trokendi XR product label with migraine as an indication in a different format prior to completing its review. No additional new data, studies or analyses for efficacy or safety were requested by the FDA.
SUPN: 21.87 (-0.16)
Supernus Announces Issuance of Sixth U.S. Patent Protecting Oxtellar XR(R)
GlobeNewswire - Thu Jun 02, 7:00AM CDT
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced the issuance on May 31, 2016 of a sixth patent (number 9,351,975) by the United States Patent and Trademark Office (USPTO) covering Oxtellar XR, its novel once-daily extended-release oxcarbazepine product. The patent provides protection for the product with expiration that is no earlier than 2027.
SUPN: 21.87 (-0.16)
Supernus to Present at June Jefferies Healthcare Conference
GlobeNewswire - Tue May 24, 4:16PM CDT
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present an overview and update of the Company and host investor meetings at the Jefferies 2016 Healthcare Conference.
SUPN: 21.87 (-0.16)
Supernus Enters Into Partial Settlement Agreement with Actavis on Oxtellar XR(R)
GlobeNewswire - Tue May 10, 7:30AM CDT
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that, pursuant to a confidential partial settlement agreement, it has dismissed two patent infringement actions pending in the U.S. District Court for the District of New Jersey against Actavis Inc. and its subsidiaries. The dismissed actions concerned two of Supernus' Orange Book patents covering Oxtellar XR(R)--U.S. Patent Nos. 8,821,930 and 9,119,791. The parties also agreed to dismiss Actavis' pending appeal (and Supernus' corresponding cross-appeal) of a February 2016 district court ruling that a third Oxtellar XR patent--U.S. Patent No. 8,617,600--is valid, but not infringed by Actavis' proposed generic version of Oxtellar XR. The February 2016 district court decision additionally found that Actavis infringed two other Oxtellar XR Orange Book patents (U.S. Patent Nos. 7,722,898 and 7,910,131), and enjoined Actavis from launching a generic version of Oxtellar XR until at least April 13, 2027. Actavis' appeal of that ruling will proceed as scheduled.
ACT: 298.98 (-2.94), SUPN: 21.87 (-0.16)
Supernus Announces First Quarter 2016 Financial Results
GlobeNewswire - Tue May 03, 4:00PM CDT
-- First quarter 2016 product prescriptions totaled 114,773, representing a 49.7% increase over the first quarter of 2015.
SUPN: 21.87 (-0.16)
Supernus to Host First Quarter 2016 Earnings Conference Call
GlobeNewswire - Tue Apr 19, 11:01AM CDT
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report the financial results for the first quarter of 2016 after 5:00 PM ET on Tuesday, May 3, 2016.
SUPN: 21.87 (-0.16)
Supernus Pharmaceuticals Selects DSG, Inc. for EDC and IWRS in Phase 3 Clinical Studies on Impulsive Aggression in Pediatric Patients Treated for Attention Deficit/Hyperactivity Disorder (ADHD)
BusinessWire - Fri Apr 01, 7:00AM CDT
DSG, a leader in electronic data capture (EDC), was selected by Supernus Pharmaceuticals, a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, to provide a fully supported eCaseLink EDC system, including IWRS Web-based Randomization-Clinical Supply, a Central lab and third-party CRO data integration, and data management services for two blinded Phase 3 clinical studies on impulsive aggression in pediatric patients being treated for Attention Deficit/Hyperactivity Disorder (ADHD). Leveraging pieces of DSG's eCaseLink system (EDC and IWRS) will allow Supernus to significantly reduce clinical trial time, reduce trial cost, improve trial accuracy, and overall provide a more effective clinical trial with greater impact.
SUPN: 21.87 (-0.16)
Covered Call Alerts For Starbucks, GW Pharmaceuticals, Supernus Pharmaceuticals, CSX and SunEdison Released By InvestorsObserver
PR Newswire - Tue Feb 09, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for SBUX, GWPH, SUPN, CSX and SUNE.
SBUX: 56.03 (-0.28), GWPH: 82.80 (+0.52), SUNE: 0.34 (unch), SUPN: 21.87 (-0.16), CSX: 28.15 (-0.03)
Latest Global Supernus Pharmaceuticals, Inc. Market Research Report Product Pipeline Review 2016 - Acute Market Reports
M2 - Fri Jan 29, 7:33AM CST
'SUPERNUS PHARMACEUTICALS, INC. - Product Pipeline Review - 2015', provides an overview of the SUPERNUS PHARMACEUTICALS, INC.'s pharmaceutical research and development focus.
SUPN: 21.87 (-0.16)
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/jxcczv/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Attention Deficit Hyperactivity Disorder (ADHD) Overview - Therapeutics Development - Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Overview - Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Comparative Analysis - Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Development by Companies - Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Investigation by Universities/Institutes - Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Attention Deficit Hyperactivity Disorder (ADHD) - Products under Development by Companies - Attention Deficit Hyperactivity Disorder (ADHD) - Products under Investigation by Universities/Institutes - Attention Deficit Hyperactivity Disorder (ADHD) - Companies Involved in Therapeutics Development - Alcobra Ltd - Amarantus Bioscience Holdings, Inc. - APeT Holding BV - Arbor Pharmaceuticals, LLC. - BCWorld Pharm Co. Ltd. - Collegium Pharmaceutical, Inc. - Curemark, LLC - Domain Therapeutics SA - DURECT Corporation - H. Lundbeck A/S - Heptares Therapeutics Limited - Highland Therapeutics, Inc. - Hisamitsu Pharmaceutical Co., Inc. - Integrative Research Laboratories Sweden AB - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Luc Therapeutics, Inc. - Medgenics Inc. - Merck & Co., Inc. - Neos Therapeutics, Inc. - NeuroDerm Ltd. - Neurovance, Inc. - P2D Bioscience - Polleo Pharma Limited - Reviva Pharmaceuticals Inc. - Samyang Biopharmaceuticals Corporation - Shire Plc - Signature Therapeutics, Inc - Sunovion Pharmaceuticals Inc. - Supernus Pharmaceuticals, Inc. - Taisho Pharmaceutical Holdings Co., Ltd. - Tris Pharma, Inc. - Vernalis Plc For more information visit http://www.researchandmarkets.com/research/jx...on_deficit
KMPH: 4.59 (+0.15), MDGN: 5.58 (+0.05), ADHD: 4.83 (+0.09), SUPN: 21.87 (-0.16), COLL: 8.92 (+0.09), DRRX: 1.64 (+0.03), NEOS: 6.90 (-0.20), NDRM: 16.23 (-0.03), MRK: 62.75 (-0.15), SHPG: 191.97 (+3.47), ITCI: 40.35 (-0.28)
Supernus Announces Distribution of Common Stock by NEA
GlobeNewswire - Fri Dec 04, 8:00AM CST
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that it has received notice that, effective following the close of trading on December 3, 2015, New Enterprise Associates (NEA) distributed an aggregate of 3,820,625 shares of Supernus Pharmaceuticals common stock to its partners, and as a result no longer holds common stock in the company. "The distribution announced today is the third and final installment of a distribution that NEA initiated earlier this year and is consistent with its customary practices. NEA distributed shares of Supernus common stock to its limited partners after holding that position for over nine years," stated Jack Khattar, president and chief executive officer of Supernus.
SUPN: 21.87 (-0.16)
Supernus to Attend Guggenheim Securities Boston Healthcare Conference
GlobeNewswire - Wed Dec 02, 3:30PM CST
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will be hosting investor meetings at the Guggenheim Securities 3 Annual Boston Healthcare Conference 2015.
SUPN: 21.87 (-0.16)
Supernus reports distribution of 3,820,625 common stock through NEA
M2 - Fri Nov 13, 3:28AM CST
Supernus Pharmaceuticals (NasdaqGM:SUPN) on Thursday announced the distribution of an aggregate of 3,820,625 common stock with the close of trading on 11 November 2015.
SUPN: 21.87 (-0.16)
Supernus Pharmaceuticals Is Dropping -- Is It a Buy?
Todd Campbell, The Motley Fool - Motley Fool - Thu Nov 12, 12:26PM CST
What: A bit more than a week after reporting earnings and ahead of an investor conference next week, shares in Supernus Pharmaceuticals fell by 13% earlier today. Let's take a closer look at this company and whether or not investors ought to...
GWPH: 82.80 (+0.52), SUPN: 21.87 (-0.16)
